FDA Denies P&G Petition For OTC Proton Pump Inhibitor Class Labeling
This article was originally published in The Tan Sheet
Executive Summary
FDA's rejection of a Procter & Gamble citizen petition seeking class labeling for OTC proton pump inhibitors clears a roadblock for Schering-Plough's Zegerid to potentially make an "immediate release" claim
You may also be interested in...
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets